Entering edit mode
3.9 years ago
anlinli.napert
•
0
Is ctDNA tumor mutation burden (TMB) (PMID: 30867242) defined as the same as the blood-based TMB (PMID: 30082870)?
Article PMID 30867242: https://www.ncbi.nlm.nih.gov/pubmed/30867242
Article PMID 30082870: https://www.ncbi.nlm.nih.gov/pubmed/30082870
Advanced thanks for answering!
Dear Kevin,
Thank you very much for your answer!!
I still have a question regarding the association of ctDNA TMB with the entire tumor heterogeneity. As you answered, "the ctDNA TMB calculation can be regarded as a best estimate of the true TMB", but "ctDNA will only reflect tumour clones that are actively shedding material into the circulatory system, either via apoptosis or necrosis".
I am not sure but I found it paradoxical. If the ctDNA only reflects partial tumour clones, why many articles said ctDNA TMB could reflect more comprehensive tumor heterogeneity then tissue-based TMB? Although ctDNA TMB could concurrently capture mutations from both primary and metastatic sites, but they only reflect mutations shed in the blood.
Regards, Anlin Li
Perhaps they mean that ctDNA TMB is a better prognostic tool, as it can be simply extracted from blood and is therefore non-invasive, and also considering the fact that ctDNA that's detected may reflect a dominant or metastasising clone.
Generally, though, 'TMB' is a 'catch all' term that refers to different ways of summarising mutation numbers and frequency. There is no standard way of calculating TMB